Branded GLP-1s (Ozempic, Wegovy, Mounjaro, Zepbound) carry higher list prices but may qualify for manufacturer copay assistance if you have any insurance
But managing them while simultaneously caring for an infant requires specific strategies that generic side effect guides do not cover
When considering adding a GLP-1 receptor agonist like Rybelsus, NICE guidance indicates these agents may be appropriate for people with type 2 diabetes who: Have a BMI of 35 kg/m or higher (adjusted for ethnicity) and specific psychological or medical problems associated with obesity, or Have a BMI lower than 35 kg/m and for whom insulin therapy would have significant occupational implications, or weight loss would benefit other significant obesity-related comorbidities GLP-1 therapy should only be continued if there is a beneficial metabolic response, defined as a reduction in HbA1c of at least 11 mmol/mol (1.0%) and weight loss of at least 3% of initial body weight at six months
This is because B vitamins are crucial in converting food into usable energy (ATP), and correcting a deficiency allows your metabolism to run more efficiently
Sales of Wegovy and Ozempic made Novo Nordisk the most valuable European company last year and helped drive an increase in profit at Lilly for the second quarter that ended June 30 by nearly 69% over the year-earlier period
